Organization | JN-International Medical Corporation

JN-International Medical Corporation Report issue

For profit Phase 1 Phase 2

Founded: Omaha NE United States (1998)

Status: No NME R&D (1998)

Organization Overview

First Clinical Trial

2011

NCT01482052

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (2)

nmvac4-a/c/y/w-135-dt (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

Drugs in Phase 1 Trials (2)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diphtheria (Phase 2)

Meningitis (Phase 2)

Meningitis, Meningococcal (Phase 2)

Meningococcal Infections (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 4